1. Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics
   Roya Tabatabai et al, 2017, Targ Oncol CrossRef
2. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology
   Michael H Kagey et al, 2017, British Journal of Pharmacology CrossRef
3. Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers
   Lauriane Chambard et al, 2018, Bone CrossRef
4. MicroRNA-1-3p inhibits the proliferation and migration of oral squamous cell carcinoma cells by targeting DKK1.
   Zhenshi Wang et al, 2018, Biochem Cell Biol CrossRef
5. A Succinate Ether Derivative of Tocotrienol Enhances Dickkopf-1 Gene Expression through Epigenetic Alterations in Malignant Mesothelioma Cells
   Ayami Sato et al, 2018, Pharmacology CrossRef
6. Negative regulators of Wnt signaling in non-small cell lung cancer: Theoretical basis and therapeutic potency
   Zikuan Song et al, 2019, Biomedicine & Pharmacotherapy CrossRef
7. Diagnostic investigations of DKK-1 and PDCD5 expression levels as independent prognostic markers of human chondrosarcoma
   Mojtaba Zarea et al, 2016, IUBMB Life CrossRef
8. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway
   Rui Zhang et al, 2019, Sig Transduct Target Ther CrossRef
9. Prognostic role of dickkopf-1 in patients with cancer
   Junfang Huang et al, 2020 CrossRef
10. Casein Kinase 1α as a Regulator of Wnt-Driven Cancer
    Chen Shen et al, 2020, IJMS CrossRef
11. Stress-activated kinases as therapeutic targets in pancreatic cancer
    Benno Traub et al, 2021, WJG CrossRef
12. The role of Wnt pathway antagonists in early-stage lung adenocarcinoma
    Arife Zeybek et al, 2021, Mol Biol Rep CrossRef